Amitriptyline

Basic Information

CAS ID: 50-48-6
Molecular Formula: C20H23N
Molecular Weight: 277.4 g/mol
Monoisotopic Mass: 277.183 g/mol
Class: Small Molecule
Natural Product: No
Other Names: LENTIZOL | Elavil | Amitid | SAROTEN RETARD | DOMICAL | AMITID | AMITRIL | Limbitrol | Etrafon-Forte | AMITRIPTYLINE HYDROCHLORIDE | TRIPTAFEN-M | Etrafon-A | ENDEP | ELAVIL | Amitril | TRIPTAFEN | LIMBITROL 5 | Amitriptyline | Endep | TRYPTIZOL | CYTRIPTYLINE | TRYPTIZOL-75 | SAROTEN
Analysis: Drug repositioning mechanism analysis

N

Compound Structure and Identifier

InChI: InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3 See All
InChI Key: KRMDCWKBEZIMAB-UHFFFAOYSA-N
Smiles: CN(C)CCC=C1c2ccccc2CCc3ccccc13 See All
Molfile: Download

Related Target

Target ID Name Interaction
T0907 Sphingomyelin phosphodiesterase inhibitor
T0943 Acidic sphingomyelinase inhibitor

Related Fibrosis Property

Reference Record 1

PubMed ID 19635928 Target ID T0907
Uniprot ID Sphingomyelin phosphodiesterase Name Sphingomyelin phosphodiesterase
Model vitro,human,mice Fibrosis Disease Cystic fibrosis
Process I attenue inflammation
Process II
Process III
Mechanism

Reference Record 2

PubMed ID 24796378 Target ID T0943
Uniprot ID Acidic sphingomyelinase Name Acidic sphingomyelinase
Model vitro,mice Fibrosis Disease Liver fibrosis
Process I
Process II HSCs activation,HSCs proliferation
Process III prevenet collagen deposition
Mechanism

Trial Record 1

ClinicalTrial ID NCT01309178 Disease Cystic fibrosis
Phase Phase 2 Status Unknown
First Received March 7, 2011 Last Verified March 7, 2011
Sponsor University Children’s Hospital Tuebingen

Trial Record 2

ClinicalTrial ID NCT00515229 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received August 13, 2007 Last Verified August 13, 2007
Sponsor University Hospital Tuebingen

Related Link

PubChem: 2160
ChEMBL: CHEMBL629